William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on TARS stock, giving a Buy rating today.
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors including Tarsus Pharmaceuticals’ impressive financial performance and strategic positioning. The company reported fourth-quarter revenue for Xdemvy that significantly exceeded both the firm’s and market expectations, showcasing strong demand and effective sales execution. The volume of Xdemvy bottles delivered surpassed guidance, indicating robust market uptake and contributing to the revenue growth.
Additionally, Tarsus is strategically positioned for continued growth with an expanded salesforce and improved insurance coverage, which now includes over 90% of commercial, Medicare, and Medicaid lives. This expansion is expected to facilitate greater prescribing depth among eye care professionals. Furthermore, management’s guidance suggests a positive outlook with anticipated growth in bottle deliveries and a decrease in gross-to-net discounts over the year, reinforcing confidence in the company’s future performance.
In another report released today, Barclays also maintained a Buy rating on the stock with a $62.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com